Is this ASX healthcare stock ready to rocket post-merger?

Integral Diagnostics (ASX:IDX) had a great year in 2024; its share price was up around 50% as its business recovered from the post-Covid doldrums. It has just completed a merger with Capitol Health to make it Australia’s second largest radiology provider and IML portfolio manager Marc Whittaker believes this has it well set up for its next phase of growth.

In this podcast Marc discusses why Integral Diagnostics is one of his highest conviction holdings in IML’s small and mid cap funds.